MP-0317 is a recombinant protein commercialized by Molecular Partners, with a leading Phase I program in Anal Cancer. According to Globaldata, it is involved in 1 clinical trial, which is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of MP-0317’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for MP-0317 is expected to reach an annual total of $19 mn by 2038 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
MP-0317 is under development for the treatment of colorectal cancer, ovarian cancer, prostate cancer, non-small cell lung cancer, cervical cancer, anal cancer, melanoma, pancreatic cancer, gastric cancer, endometrial cancer, urothelial/bladder cancer, head and neck squamous cell carcinoma, breast cancer, mesothelioma and cutaneous squamous cell carcinoma. The therapeutic candidate is a bi-specific protein that acts by targeting CD40 and fibroblast activating protein (FAP) which is expressed in stroma of many tumor cells. It is administered by intravenous route and developed based on designed ankyrin repeat proteins (DARPin) technology.
Molecular Partners Overview
Molecular Partners is a clinical-stage biopharmaceutical company that develops biological drugs. The company offers advanced small protein therapies such as abicipar, a designed ankyrin repeat protein-based anti-angiogenic drug developed for diabetic macular edema and wet age-macular degeneration. Its product pipeline includes MP0317- FAP x CD40, MP0533 -CD3 x CD33+CD70+CD123 and sars-cov-2: COVID. Molecular Partners develops products for ophthalmic conditions, cancer, immune disorders and other indications It also develops drugs on DARPin base technology and other product candidates. The company also provides clinical trial services and small protein therapies. Molecular Partners is headquartered in Zurich, Switzerland.
The company reported revenues of (Swiss Francs) CHF189.6 million for the fiscal year ended December 2022 (FY2022), compared to a revenue of CHF9.8 million in FY2021. The operating profit of the company was CHF116.6 million in FY2022, compared to an operating loss of CHF63.4 million in FY2021. The net profit of the company was CHF117.9 million in FY2022, compared to a net loss of CHF63.8 million in FY2021.
For a complete picture of MP-0317’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.